Meanwhile, pancreatic cancer stem cells rely on mitochondrial OXPHOS, which may be correlated with the suppression of MYC and the MYC/PGC-1α ratio, so mitochondrial agents and genetic therapy can easily target this phenotype [31]. This evidence concerns the gene MYC and pancreatic neoplasm.